Q3 2024 revenue declined 15.97% year-over-year, with net profit down 62.28% amid international registration delays and domestic margin pressure. The company is focusing on cost control, boosting reagent sales, and high-speed equipment deployment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.